Cancer theranostic applications of lipid-based nanoparticles

• Published in: Drug discovery today Vol. 23; no. 5; pp. 1159 - 1166
• Main Authors: Tang, Wei-Lun, Tang, Wei-Hsin, Li, Shyh-Dar
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.05.2018
• ISSN: 1359-6446; 1878-5832
• DOI: 10.1016/j.drudis.2018.04.007

•LNPs can be doped with multiple components for theranostics.•LNPs allow versatile multimodal imaging and therapy of cancer.•LNPs empower image-guided drug targeting.•Feasibility of multifunctional LNPs in scale-up manufacturing must be considered. A variety of nanoplatforms have been developed and applied for cancer therapy, imaging, or the combination thereof. These nanoplatforms, combined with therapeutic and imaging functionalities, display great potential to enhance medical care. In particular, lipid-based nanoparticles (LNPs) are among the most-studied platforms that have resulted in many encouraging advances in theranostics. LNPs are biodegradable and biocompatible, and their formulation can be tailored for various applications. Here, we provide an overview of recent developments of four representative LNP platforms for theranostics: stealth liposomes, triggered-release liposomes, porphysomes, and lipid-coated calcium phosphate NPs (LCPs). We discuss their potential, limitations, and potential applications for cancer care and highlight perspectives and future directions for the nanotheranostics field.